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Available online 2 December 2015Cellular signalingmediated by the EGF receptor (EGFR) plays a key role in controlling proliferation and differen-
tiation of cortical progenitor cells (CPCs). However, regulatory mechanisms of EGFR signaling in CPCs remain
largely unknown. Here we demonstrate that necdin, a MAGE (melanoma antigen) family protein, interacts
with EGFR in primary CPCs and represses its downstream signaling linked to astrocyte differentiation.
EGFR was autophosphorylated and interacted with necdin in EGF-stimulated CPCs. Necdin bound to
autophosphorylated EGFR via its tyrosine kinase domain. EGF-induced phosphorylation of ERK was enhanced
in necdin-null CPCs, where the interaction between EGFR and the adaptor protein Grb2 was strengthened, sug-
gesting that endogenous necdin suppresses the EGFR/ERK signaling pathway in CPCs. In necdin-null CPCs, astro-
cyte differentiation induced by the gliogenic cytokine cardiotrophin-1 was signiﬁcantly accelerated in the
presence of EGF, and inhibition of EGFR/ERK signaling abolished the acceleration. Furthermore, necdin strongly
suppressed astrocyte differentiation induced by overexpression of EGFR or its ligand binding-defective mutant
equivalent to a glioblastoma-associated EGFR variant. These results suggest that necdin acts as an intrinsic
suppressor of the EGFR/ERK signaling pathway in EGF-responsive CPCs to restrain astroglial development in a
cell-autonomous manner.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Necdin
EGFR
ERK
Gliogenesis
MAGE family1. Introduction
The growth factors EGF and bFGF (also known as FGF-2) are indis-
pensable for maintaining the self-renewal and multipotency of neural
stem cells residing in developing mammalian telencephalon [1–4].
CPCs proliferate and differentiate into neuronal progenitors in response
to bFGF at early stages of embryonic cortical development and into glial
progenitors in response to EGF at the late stages [5–8]. These temporal
changes of CPCs in the responsiveness to EGF and bFGF are involved in
the generation of speciﬁc cell types during cortical development [9].
The EGF receptor (EGFR, also known as ErbB1 or HER1), amember of
the receptor tyrosine kinase family, is expressed in the embryonic cor-
tex, and its expression levels are low during the early period and high
during the late period [8,10]. Mutantmice lacking the EGFR gene exhibit
abnormal development and postnatal neurodegeneration in ther; CPC, cortical progenitor cell;
y; TKD, tyrosinekinase domain;
ctivated protein kinase kinase;
antigen; PWS, Prader–Willi
n of Neuronal Development,
ka 565-0871, Japan.
shikawa).
. This is an open access article undercerebral cortex [11,12], indicating that EGFR plays an important role in
normal cortical development. EGFR is asymmetrically distributed in a
subset of CPCs and differentially inherited by their daughter cells,
which exhibit different responsiveness to EGF in a developmental
stage-dependent manner [8]. Furthermore, EGFR promotes the differ-
entiation and proliferation of astrocytes at late embryonic and neonatal
stages of cortical development [5,7,12,13]. Thus, the temporal and spa-
tial differences in EGFR expression contribute to the fate diversiﬁcation
of CPCs by changing their responsiveness to EGF during normal cortical
development. However, there is limited information about regulatory
mechanisms of EGFR signaling in CPCs.
Necdin is expressed abundantly in postmitotic neurons and moder-
ately in neural precursor cells [14–17]. Necdin interacts with major
nuclear proteins such as E2Fs, p53 and Sirt1 to suppress mitosis of
proliferative cells and promote neuronal survival [18–21]. Necdin also
interacts with the NGF receptor TrkA, another receptor tyrosine kinase,
to promote differentiation and survival of sensory neurons [22]. More-
over, a study using yeast two-hybrid screening has identiﬁed necdin
as one of the EGFR-interacting proteins [23]. These ﬁndings prompted
us to investigate the physical and functional interactions between
EGFR and necdin in CPCs.
In this study, we demonstrate that necdin interacts with EGFR in its
active state to suppress the EGFR/ERK signaling pathway in primarythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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duced by EGF-dependent activation of the EGFR/ERK signaling pathway
in CPCs. Furthermore, necdin inhibits astroglial differentiation induced
by overexpression of EGFR and its ligand-binding defective mutant. Be-
cause dysregulation of EGFR signaling has been proposed to contribute
to the malignant transformation of astrocytes or astroglial progenitors,
these observations provide insights into themolecularmechanisms un-
derlying gliogenesis and gliomagenesis via EGFR signaling pathway
under physiological and pathological conditions.
2. Materials and methods
2.1. Primary cortical progenitor cells
Neocortical tissues were dissected from mouse embryos at em-
bryonic day (E) 14.5, incubated for 5 min at 37 °C in Ca2+/Mg2+-
free glucose-supplemented HBSS with 0.05% trypsin, dissociated in
DMEM supplemented with 10% fetal bovine serum, and centrifuged
at 200 ×g for 3 min to obtain cell pellets. Resuspended cells were in-
cubated at 37 °C under humidiﬁed 5% CO2 conditions in CPC medium
containing DMEM/F12 (Thermo Fisher Scientiﬁc), B-27 (1:50 dilu-
tion; Thermo Fisher Scientiﬁc), 14 mM sodium bicarbonate, 1 mM
N-acetyl-L cysteine, 33mMD (+)-glucose, 1 mg/ml bovine serum al-
bumin, 2 mM GlutaMAX (Thermo Fisher Scientiﬁc), kanamycin/pen-
icillin, and 20 ng/ml bFGF (PeproTech). CPCs were grown as ﬂoating
spheres, dispersed with TrypLE (TrypLE Select; Thermo Fisher Scientif-
ic), and passaged every 48h unless stated otherwise. Necdin gene (Ndn)
mutant mice were generated and maintained as described previously
[22]. Heterozygous male mice (Ndn+/−) (N25 generations in the ICR
background) were crossed with wild-type female mice (Ndn+/+)
(Japan SLC) to obtain wild-type (Ndn+m/+p) and paternal Ndn-
deﬁcient (Ndn+m/−p) littermates. All mice were housed in a 12 h
light/dark cycle with room temperature at 23 ± 3 °C. Pregnant female
mice at gestation day 14.5 were sacriﬁced by cervical dislocation, and
embryos were collected. Genotypes of all mice were analyzed for mu-
tated Ndn locus. The study was approved by the Animal Experiment
Committee (Approval No. 24-04-0) and Recombinant DNA Committee
(Approval No. 3642) of Institute for Protein Research, Osaka University,
and were performed in accordance with national, institutional, and the
ARRIVE guidelines.
2.2. Immunoblot analysis
CPCs and brain tissues were homogenized with a lysis buffer con-
taining 10 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1% IGEP
AL CA-630 (MP Biomedicals), 10% glycerol, and protease inhibitors
(Complete, Roche Diagnostics). The protein concentration was deter-
mined by the Bradford method (Bio-Rad). Proteins (10 μg per lane)
were separated by 9% SDS-PAGE, and electroblotted to polyvinylidene
diﬂuoride membranes (Immobilon, Merck Millipore). Membranes
were incubated with primary antibodies against EGFR (1005; 1:100;
Santa Cruz Biotechnology), necdin (NC243; 1:3000) [24], nestin (ST-1;
1:1000) [25], γ-tubulin (GTU-88; 1:1000; Sigma-Aldrich), phospho-
EGFR (Tyr1068) (D7A5; 1:1000; Cell Signaling Technology), PCNA
(PC10; 1:1000; Santa Cruz Biotechnology), Myc (9E10; 1:10),
phospho-ERK1/2 (E10; 1:1000; Cell Signaling Technology), ERK1/2 (K-
23; 1:3000; Santa Cruz Biotechnology), phospho-Akt (193H12; 1:500;
Cell Signaling Technology), Akt (1:500; Cell Signaling Technology),
Grb2 (C-7; 1:300; Santa Cruz Biotechnology), Sos1 (C-23; 1:1000;
Santa Cruz Biotechnology), glial ﬁbrillary acidic protein (GFAP)
(1:1000; gift from Dr. Seiichi Haga, Tokyo Metropolitan Institute of
Medical Science), and FLAG (M2; 1:500; Sigma-Aldrich). After incuba-
tion with peroxidase-conjugated IgGs (Cappel), the proteins were visu-
alized by chemiluminescence method (Chemiluminescence Reagent
Plus, PerkinElmer). Signal intensities were measured by densitometry
and quantiﬁed using NIH ImageJ 1.46 software.2.3. Immunocytochemistry
Primary CPCs were dispersed with TrypLE Select, plated onto 24-
well plates precoated with poly-L-ornithine (Sigma-Aldrich), and
incubated for 3 h. Cells were ﬁxed with 10% formalin solution at room
temperature for 20 min and permeabilized with methanol at room
temperature for 20 min. For EGFR staining, cells were ﬁxed with 4%
paraformaldehyde in phosphate buffer (pH 7.4) and permeabilized
with 0.02% Tween 20 in PBS at room temperature for 10 min. Fixed
cells were incubated with primary antibodies at 4 °C overnight, and
with secondary antibodies at room temperature for 90 min. The pri-
mary antibodies used are against EGFR (1005; 1:50), necdin (GN1;
1:1000) [22], nestin (ST-1; 1:1000), phospho-EGFR (D7A5; 1:100),
GFAP (1:1000), βIII-tubulin (5G8; 1:1000; Promega), and RFP (3G5,
1:100, MBL). The secondary antibodies Alexa 488-conjugated anti-
rabbit IgG (1:500), Alexa 555-conjugated anti-guinea pig IgG
(1:500), and Alexa 555-conjugated anti-rabbit IgG (1:500) were
purchased from Molecular Probes. Nuclear DNA was counterstained
with 3.3 μM Hoechst 33342 (Sigma-Aldrich). Images were observed
with a ﬂuorescence microscope (BX51, Olympus) equipped with
charge-coupled device camera system (DP73, Olympus) or by confo-
cal laser scanning microscopy (FV1000 BX61, Olympus), and proc-
essed using Adobe Photoshop CS5 software.2.4. Coimmunoprecipitation assay
For detection of endogenous binding between necdin and EGFR, ly-
sates of CPCs (1 mg protein) cultured in the CPC medium for 4 days
were incubated with guinea pig anti-necdin IgG (GN1; 1:10) [22] or
preimmune IgG. Bound proteins were isolated with Dynabeads protein
A (Thermo Fisher Scientiﬁc) and detected by immunoblotting with an-
tibodies against phospho-EGFR (D7A5; 1:1000), EGFR (1005; 1:100)
and necdin (NC243; 1:3000). For interactions between necdin and
EGFR mutants in transfected cells, HEK293A cells were transfected
with combinations of expression vectors by the calcium phosphate
method and harvested after 24 h. Cell lysates (150 μg protein) were in-
cubated at 4 °C for 2 h with antibodies against Myc (9E10; 1:4) and
necdin (NC243; 1:100), pelleted with Protein A-Sepharose (GE
Healthcare), separated by 9% SDS-PAGE, and detected by immunoblot-
ting. Full-length mouse EGFR cDNA (NCBI NM 207655.2) was synthe-
sized by RT-PCR from mRNA expressed in CPCs. cDNAs encoding EGFR
deletion mutants and its point mutants were generated using synthetic
oligonucleotide primers based on their sequence information (NCBI NM
207655.2) and subcloned into 6xMyc-pcDNA3.1+. For interactions of
EGFR with Grb2 and Sos1, primary CPCs prepared from E14.5 mice
were cultured for 4 days and treated with EGF (10 ng/ml) for 5 min.
CPC lysates (500 μg protein) were incubated with antibodies to Grb2
(C-7; 1:100) and Sos1 (C-23; 1:100). Bound proteins were pelleted
with Protein A-Sepharose and detected by immunoblottingwith the an-
tibody to EGFR (1005; 1:100).2.5. In vitro binding assay
The tyrosine kinase domain (TKD) of EGFR and its deletion mutants
were generated using synthetic oligonucleotide primers based on their
sequence information (NCBI NM 207655.2) and subcloned into pMAL-
C2 vector to make maltose binding protein (MBP) fusion proteins.
MBP-fused proteins were afﬁnity-puriﬁed with amylose resin (New
England Biolabs) and incubated with His-tagged necdin (200 ng) at 4
°C for 30 min in 0.5 ml of the binding buffer containing 20 mM Tris–
HCl (pH 7.5), 200 mM NaCl, and 1 mM EDTA [21]. After washing,
boundHis-tagged necdin was eluted with 20mMmaltose and detected
by immunoblotting with anti-necdin antibody. MBP fusion proteins
were detected by Coomassie Brilliant Blue staining.
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Primary CPCs were prepared from E14.5 mice and incubated for
48 h. Cells (2 × 105 cells) were replated in 35-mm dishes, incubated
in the presence or absence of 20 ng/ml EGF for another 48 h, and har-
vested for manual cell counting. For EdU incorporation, CPCs at 4 day
in vitro (DIV) were plated onto poly-L-ornithine-coated coverslips.
Cells were cultured in the CPC medium supplemented with 10 ng/ml
EGF for 24 h and ﬁxed with 10% formalin solution at room tempera-
ture for 20 min, and permeabilized with methanol at room tempera-
ture for 20 min. EdU (Invitrogen, A10044; 10 μM) was added to the
CPC medium 4 h before ﬁxation. Fixed cells were incubated for
30 min with 3.3 μM Hoechst 33342 (Sigma-Aldrich) and then with
EdU detection cocktail (A10044, Invitrogen) at room temperature
for 15 min.2.7. Cell differentiation assay
For astrocyte differentiation assay, CPCs cultured for 48 h in the CPC
medium were incubated in the presence and absence of 20 ng/ml EGF
for 48 h. CPCs were dissociated and plated onto poly-L-ornithine-
coated coverslips in the CPC medium supplemented with 50 ng/ml
cardiotrophin-1 (CT-1) (PeproTech) for 48 h. GFAP-immunopositive
cells were detected by immunocytochemistry as above. For neuronal
differentiation assay, CPCs cultured for 48 h in the CPC medium were
incubated in the presence and absence of 20 ng/ml EGF for 48 h. CPCs
were dissociated, plated onto poly-L-ornithine-coated coverslips and
cultured in the CPC medium deprived of EGF and bFGF for 24 h. βIII
tubulin-expressing cells were detected by immunocytochemistry as
above.Fig. 1. EGFR and necdin are coexpressed in primary CPCs. (A) CPCs were prepared from the neo
Expression of EGFR, necdin, nestin, and γ-tubulin (γ-Tub) was analyzed by immunoblotting. (
served by confocal microscopy. Nuclear DNAwas counterstainedwithHoechst33342 (blue) and
Expression of phospho-EGFR (pEGFR) and total EGFR (EGFR) was analyzed by immunoblotting
merged. Scale bars; 10 μm (in B) 5 μm (in D).2.8. Kinase inhibitor assay
CPCswere cultured in the CPCmedium for 48 h, and EGF (10 ng/ml)
in the presence of the EGFR tyrosine kinase inhibitor geﬁtinib (5 μM;
Cayman Chemical), mitogen-activated protein kinase kinase (MEK)
inhibitor U0126 (20 μM; Merck Millipore) and phosphoinositide 3-
kinase (PI3K) inhibitor LY294002 (20 μM; Merck Millipore) were
added to the CPC medium 30 min before treatment with EGF. CPCs
were treatedwith EGF (10 ng/ml) for 5min and harvested for immuno-
blot analysis of phospho-EGFR, phospho-ERK, and phospho-Akt. For
GFAP expression assay, CPCs were treated with EGF and the kinase
inhibitors for 6 h, replated in 35-mm dish precoated with poly-L-
ornithine, and treated with CT-1 (50 ng/ml) for 48 h. Expression of
GFAP was analyzed by immunoblotting.
2.9. In vitro electroporation
CPCs were prepared from E14.5 mice and cultured for 48 h. CPCs
were centrifuged and resuspended at 5 × 106 cells in 100 μl of Opti-
MEM containing expression vectors (total DNA, 20 μg). Electric
pulses (pore pulse; 125 V/10 msec × 1: transfer pulse; 20 V/50
msec/50 msec interval; 10 cycles) were applied to the cell suspen-
sion in 2-mm gap cuvette using a pulse generator (CUY21-EDIT II,
BEX). cDNA encoding EGFR lacking residues 6–273 (EGFRΔNT) was
generated using synthetic oligonucleotide primers based on their
sequence information (NCBI NM 207655.2) and subcloned into
6xMyc-pcDNA3.1+. cDNAs for EGFR, EGFR mutants (KR and ΔNT),
FLAG-tagged mouse necdin, necdinΔEB (residues 144–184 deletion
mutant) [26], FLAG-tagged human MAGEA1 [27], and td-Tomato
(ptdTomato-N1, Clontech) were transfected into primary CPCs.
Transfection efﬁciency was ~70% as analyzed 12 h after transfectioncortex at E14.5 and cultured in the presence of bFGF (bFGF+) for the indicated durations.
B) CPCs were immunostained for EGFR (green), necdin (red), and nestin (green) and ob-
mergedwith confocal images. (C) CPCswere treatedwith EGF for the indicated durations.
or (D) immunocytochemistry. Confocal images (green) and nuclear DNA stain (blue) are
97I. Fujimoto et al. / Cellular Signalling 28 (2016) 94–107by ﬂuorescence immunocytochemistry for td-Tomato expression.
Expression of transfected cDNAs was analyzed by immunoblotting
12 h after electroporation. For GFAP expression, transfected CPCs
were cultured for 24 h in the CPC medium and treated with CT-1
(50 ng/ml) for 48 h. GFAP expression of transfected CPCs was ana-
lyzed by immunoblotting and ﬂuorescence immunocytochemistry
using antibodies to GFAP and RFP for td-Tomato.
2.10. Statistics
Statistical signiﬁcance was tested using an unpaired Student's t
test or one-way ANOVA followed by Tukey–Kramer post hoc test. A
signiﬁcance of P b0.05 was required for rejection of the null
hypothesis.Fig. 2. Autophosphorylated EGFR and necdin are colocalized in primary CPCs. (A, B) Immunocy
EGFR (green) (A) or phospho-EGFR (pEGFR) (green) (B) and necdin (red) were immunostain
(blue) are merged (Merge) for colocalization (yellow). (C) Three-dimensional analysis. CPCs w
microscopy. Multiple z-stack images in XY, XZ and YZ axes are shown. Scale bars; 10 μm(in A, B)
and necdin-null (KO) mice and treated at 4 DIV with EGF (EGF+) or without (EGF−) EGF f
preimmune IgG (Pre IgG). pEGFR, EGFR, and necdin were analyzed by immunoblotting. Lysate3. Results
3.1. EGFR expression is induced by bFGF in primary CPCs
We ﬁrst analyzed the expression levels of EGFR and necdin in prima-
ry CPCs prepared from the mouse cortex at E14.5 by immunoblotting
(Fig. 1A). When CPCs were treated with bFGF for up to 4 DIV, the
EGFR levels increased in CPCs incubated in the presence of bFGF for
2 days ormore,whereas necdinwas expressed in a constitutivemanner.
The neural stem/progenitor cell marker nestin was also expressed in
these CPCs. Immunocytochemical analysis showed that EGFRwas hard-
ly detectable in CPCs at 1 DIV but was clearly detected at the plasma
membrane and in the cytoplasm at 4 DIV, whereas necdinwas predom-
inantly cytoplasmic at 1 and 4DIV (Fig. 1B). Thus,we usedCPCs culturedtochemistry. CPCs at 4 DIV were treated with (EGF+) or without (EGF−) EGF for 5 min.
ed and observed by confocal microscopy. Immunostained images and nuclear DNA stain
ere double immunostained for pEGFR (green) and necdin (red), and observed by confocal
, 5 μm(in C). (D) Coimmunoprecipitation assay. CPCswere prepared fromwild-type (WT)
or 5 min. Cell lysates were immunoprecipitated with anti-necdin IgG (αNecdin IgG) or
, CPC lysate (10 μg).
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following experiments.
We then analyzed autophosphorylation of EGFR in EGF-stimulated
CPCs. Autophosphorylation of EGFR (phospho-EGFR), which was de-
tected with a site-speciﬁc anti-phosphotyrosine antibody against
pY1068, increased markedly in CPCs 5 min after EGF treatment
(Fig. 1C). The levels of the total EGFR and phospho-EGFR levels
decreased at 120 min. Consistent with the immunoblot results, the
phospho-EGFR immunoreactivity increased in the cytoplasm at 5 and
30 min, and both phospho-EGFR and total EGFR levels were reduced
at 120 min (Fig. 1D). These results suggest that autophosphorylated
EGFR undergoes degradation in primary CPCs.Fig. 3. Necdin interacts with the tyrosine kinase domain of EGFR. (A) Diagrams of EGFR and its
residue deletion;ΔC240, C-terminal 240 residue deletion;ΔC497, C-terminal 497 residue delet
rosine residues. (B) HEK293A cells were co-transfected with cDNAs for Myc-tagged EGFR (WT
necdin, and immunoblotted (IB) for necdin, Myc, and γ-tubulin (γ-Tub). Results are shown in A
TKD; TKDΔC91, C-terminal 91 residue deletion; TKDΔC30, C-terminal 30 residuedeletion; TKD-
CH, C-helix; AL, activation loop. (D) Coimmunoprecipitation assay for TKD-deletionmutants. HE
lysates were immunoprecipitated (IP)with antibodies to Myc and necdin and immunoblotted (
binding protein (MBP)-fused EGFRdeletionmutants immobilized on amylose resinwere incuba
ting with anti-necdin antibody (upper panel). MBP-EGFR TKD mutants were separated by 7.5%3.2. Necdin and phosphorylated EGFR colocalize in the cytoplasm of CPCs
We investigated whether EGFR and necdin are colocalized in
primary CPCs (Fig. 2A). Immunocytochemistry showed that EGFR was
localized at the plasma membrane and in the cytoplasm of CPCs.
When CPCs were treated with EGF, EGFR was accumulated in the
cytoplasm, and the EGFR immunoreactivity overlapped partially with
the necdin immunoreactivity. We also analyzed the colocalization of
autophosphorylated EGFR and necdin in CPCs (Fig. 2B). The phospho-
EGFR immunoreactivity was hardly detected in unstimulated CPCs but
increased appreciably in the cytoplasm of EGF-treated CPCs, where
it overlapped partially with that of necdin. Furthermore, three-C-terminal-truncated mutants. WT, wild-type; KR, K723Rmutant; ΔC126, C-terminal 126
ion; TM, transmembrane domain; TKD, tyrosine kinase domain; Y, autophosphorylated ty-
, KR) and necdin. Cell lysates were immunoprecipitated (IP) with antibodies to Myc and
. (C) Diagrams of TKD deletionmutants. TKD-WT, wild-type TKD; TKD-KR, K723Rmutant
C91, C-terminal 91 residues; TKD-C30, C-terminal 30 residues; PL, phosphate-binding loop;
K293A cells were co-transfectedwith cDNAs forMyc-tagged TKDmutants and necdin. Cell
IB) for necdin andMyc. Results are shown in C. (E) In vitro binding assay. Puriﬁedmaltose-
tedwithHis-tagged necdin (His-Necdin). BoundHis-necdinwas detected by immunoblot-
SDS-PAGE and stained with Coomassie Brilliant Blue (lower panel).
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EGFR and necdin were colocalized under the plasma membrane
(Fig. 2C). We then analyzed the interaction between endogenous
necdin and EGFR in CPCs by coimmunoprecipitation assay (Fig. 2D).
Phospho-EGFR and total EGFR were coprecipitated with necdin in the
lysate of wild-type CPCs treated with EGF. Although expression levels
of total EGFR were similar between EGF-treated and untreated CPCs,
necdin failed to interact with EGFR in wild-type CPCs without EGFFig. 4. Necdin suppresses the EGFR/ERK signaling pathway in CPCs. (A, B) EGF-induced phosph
(NdnKO)mice at E14.5were cultured for 4 days and treatedwith EGF (10ng/ml) for the indicate
ERK (pERK), ERK, phospho-Akt (pAkt), Akt, necdin, and γ-tubulin. pEGFR, pERK and pAkt level
tively, and then to γ-tubulin (B). Each value represents themean± SEM, n=3 (pEGFR), n=4
post hoc test. (C, D) Interactions of EGFR with Grb2 and Sos1 in EGF-stimulated CPCs. CPCs a
immunoprecipitated (IP) with antibodies to Grb2 and Sos1 and immunoblotted (IB) for
EGFR coprecipitated with Grb2 and Sos1 were normalized to those of Grb2 and Sos1, respec
Sos1, n= 4). P-values were calculated using Student's t-test.treatment. This indicates that necdin binds only to phospho-EGFR. To-
gether, these results suggest that endogenous necdin and phospho-
EGFR form a stable complex in EGF-stimulated CPCs.
3.3. Necdin interacts with the tyrosine kinase domain of EGFR
To characterize the interaction between necdin and EGFR, we per-
formed the coimmunoprecipitation assay using transfected HEK293Aorylation of EGFR, ERK, and Akt. CPCs prepared from wild-type (NdnWT) and necdin-null
d durations. CPC lysateswere immunoblotted for phospho-EGFR (pEGFR), EGFR, phospho-
s were quantiﬁed by densitometry and normalized to those of EGFR, ERK and Akt, respec-
(pERK, pAkt). P-values were calculated using one-way ANOVA followed by Tukey–Kramer
t 4 DIV were treated with (EGF+) or without (EGF−) EGF for 5 min. CPC lysates were
EGFR, Grb2, Sos1, pEGFR, pERK, ERK, necdin, and γ-tubulin (C). Signal densities of
tively, and then to γ-tubulin (D). Each value represents the mean ± SEM (Grb2, n = 6;
100 I. Fujimoto et al. / Cellular Signalling 28 (2016) 94–107cells. In mouse EGFR cDNA-transfected HEK293A cells, overexpressed
EGFR underwent ligand-independent autophosphorylation (Fig. S1A).
To validate the assay system, we tested the interactions of necdin with
wild-type EGFR and its kinase dead (K723R) mutant using the adaptor
protein Grb2 as a positive control (Fig. S1B). Both necdin and Grb2
bound preferentially to wild-type EGFR, suggesting that necdin binds
to EGFR only in its active state.
We then examined the interactions of necdin with EGFR deletion
mutants that lack 126 and 240 amino acid residues of the C-tail con-
taining autophosphorylated tyrosine residues (Fig. 3A). Necdin was
expressed in transfected HEK293A cells as major 42 kDa and minor
37 kDa proteins (the minor protein is presumably a degraded prod-
uct of the 42 kDa protein). In this assay, necdin bound to wild-type
EGFR (WT) and an EGFR mutant lacking C-terminal 126 residues
(WTΔC126) (Fig. 3B). Notably, necdin strongly bound to the deletion
mutants WTΔC240 and KRΔC240 lacking the entire C-terminal 240
residues. These results suggest that the C-tail of EGFR interferes
with the interaction between necdin and EGFR. Necdin failed to in-
teract with an EGFR mutant (ΔC497) lacking both the C-tail and
the tyrosine kinase domain (TKD) (residues 690–946), indicating
that necdin binds to the TKD.
To determine the necdin-binding region of the TKD, we constructed
Myc-tagged TKD deletion mutants (Fig. 3C). Necdin bound towild-type
TKD and the TKD KRmutant, but not to wild-type TKDΔC91 lacking the
C-terminal 91 residues in the C-lobe (Fig. 3D). In contrast, necdinFig. 5.Necdin suppresses EGF-promoted proliferation of CPCs. (A, B) Total CPC count. CPCs prepa
replated at 2 × 105 cells per 35-mm dish, and cultured in the presence (EGF+) or absence (EGF
presented as fold change (B). (C–E) EdU incorporation assay. CPCs were cultured for 96 h, rep
absence (EGF−) of EGF for 24 h, and ﬁxed for ﬂuorescence microscopy (D). EdU was added to
stained (green, arrowheads). EdU+ cells were counted (each N190 DNA-stained cells examined
using one-way ANOVA followed by Tukey–Kramer post hoc test. NS, not signiﬁcant at P ≥0.05.strongly interacted with the C-terminal 91 residues (C91). The necdin-
binding region was narrowed down to the C-terminal 30 residues
of the TKD (TKD-C30). To test whether necdin directly binds to the
TKD-C30 region, we performed in vitro pull-down assay using MBP-
fused wild-type EGFR TKD (WT), TKD mutants (TKDΔC30 and TKD-
C30), and His-tagged necdin (Fig. 3E). Consistent with the results of
coimmunoprecipitation assay, His-tagged necdin bound to wild-type
TKD and TKD-C30, but not to TKDΔC30, indicating that necdin binds di-
rectly to the C-terminal region (residues 917–946) of the TKD.
3.4. Necdin suppresses phosphorylation of ERK via inhibition of the
interaction between EGFR and Grb2
To examine whether endogenous necdin affects the tyrosine kinase
activity, we analyzed EGF-induced autophosphorylation of EGFR in
necdin-null CPCs (Fig. 4A, B). Immunoblot analysis showed that
phospho-EGFR levels were not signiﬁcantly changed in necdin-null
CPCs (Fig. 4A, top panel; Fig. 4B, top graph). We also examined the
effects of necdin on the EGFR signaling pathways by analyzing the
phosphorylation levels of ERK and Akt. In this analysis, minor and
major ERK bands at 44 kDa (ERK1) and 42 kDa (ERK2) were detected.
Notably, phospho-ERK levels in necdin-null CPCs increased ~2-fold at
5 min in response to EGF (Fig. 4A, 3rd panel; Fig. 4B, middle graph). In
contrast, phospho-Akt levels were not signiﬁcantly changed in necdin-
null CPCs (Fig. 4A, 5th panel, Fig. 4B, bottom graph).red fromwild-type (NdnWT) and necdin-null (NdnKO) E14.5micewere cultured for 48 h,
−) of EGF for another 48 h (A). Cells were harvested for manual cell counting (n=4) and
lated onto poly-L-ornithine-precoated 24-well plates, cultured in the presence (EGF+) or
the medium 4 h before ﬁxation, and EdU incorporated into nuclear DNA was chemically
, n=3), and the EdU+ population is presented as percentage (E). P-values were calculated
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pathway, we examined the interactions of EGFR with the adaptor pro-
tein Grb2 and the Grb2-binding RAS activator Sos1 in wild-type and
necdin-null CPCs (Fig. 4C). The amount of EGFR coprecipitated with
Grb2 or Sos1 increased markedly (~2.5-fold) in necdin-null CPCs treat-
ed with EGF (Fig. 4C, top and 3rd panels, Fig. 4D). Grb2 failed to interact
with necdin as analyzed by coimmunoprecipitation using transfected
HEK293A (Fig. S2). These results suggest that necdin suppresses the
interaction between EGFR and Grb2 to downregulate the RAS/ERK
signaling in CPCs.Fig. 6.Necdin suppresses EGF-promoted astrocyte differentiation of CPCs. (A–C)Astrocyte differ
E14.5were cultured for 48h, treatedwith (EGF+)orwithout (EGF−) EGF for 48 h, and thenwi
counted (each N170 cells examined, n=3) (C). (D–F) Neuronal differentiation assay. CPCswer
the medium deprived of EGF and bFGF for 24 h (D). CPCs were immunostained for βIII-tubuli
Immunostained images are merged with nuclear DNA stain (B, E). Scale bars, 50 μm (in B, E).
ANOVA followed by Tukey–Kramer post hoc test. NS, not signiﬁcant at P ≥0.05.3.5. Necdin suppresses proliferation of EGF-responsive CPCs
Because the EGFR/ERK pathway is involved in the control of cellular
proliferation, we next examined whether necdin affects the prolifera-
tion rate of primary CPCs (Fig. 5A, B). When CPCs were treated with
EGF for 48 h, the total cell number of CPCs increased signiﬁcantly
(1.37 times the wild-type control level) in necdin-null CPCs, whereas
there was no signiﬁcant difference in the absence of EGF. We also
used EdU incorporation assay to determine the proliferation rate of
CPCs prepared from wild-type and necdin-null mice (Fig. 5C–E). Theentiation assay. CPCsprepared fromwild-type (NdnWT) and necdin-null (NdnKO)mice at
th CT-1 for 48h (A). CPCswere immunostained for GFAP (green) (B), and GFAP+ cellswere
e cultured for 48 h, treatedwith (EGF+) or without (EGF−) EGF for 48 h and incubated in
n (red) (E), and βIII-tubulin+ cells were counted (each N300 cells examined, n= 3) (F).
Each value represents the mean ± SEM (in C, F). P-values were calculated using one-way
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cantly (1.35 times the wild-type control level). These results suggest
that endogenous necdin suppresses EGF-stimulated proliferation of
primary CPCs through inhibition of the EGFR/ERK pathway.
3.6. Necdin suppresses astrocyte differentiation in EGF-responsive CPCs
CPCs differentiate into astrocytes in response to the interleukin-6
(IL-6) family of cytokines such as CNTF and LIF [28–30]. EGFR regulates
the competence of CPCs to interpret LIF as an astrocyte-inducing signal
[13]. To investigate whether necdin affects astrocyte differentiation of
CPCs by suppressing EGFR signaling, we used cardiotrophin-1 (CT-1),
one of the IL-6 family cytokines [31,32], to induce astrocyte differentia-
tion of CPCs (Fig. 6A–C). The number of GFAP+ astrocytes differentiated
from necdin-null CPCs increased by 39% in the presence of EGF and CT-
1, whereas the GFAP+ cell population was not signiﬁcantly changed in
necdin-null CPCs in the absence of EGF. These results indicate that
endogenous necdin suppresses EGF-promoted glial differentiation via
inhibition of the EGFR/ERK signaling.
In this analysis, we found that the GFAP immunoreactivity increased
appreciably in each GFAP-expressing cell differentiated from necdin-
null CPCs (Fig. S3A). Thus, we analyzed the expression levels of the
GFAP protein by immunoblotting (Fig. S3B). EGF markedly increasedFig. 7.Necdin suppresses EGF-promotedGFAP expression in CPCs. (A) Effects of kinase inhibitor
EGFR tyrosine kinase inhibitor (ETKI, geﬁtinib; 5 μM), MEK inhibitor (MEKI, U0126; 20 μM) an
treatment. Phospho-EGFR (pEGFR), phospho-ERK (pERK), and phospho-Akt (pAkt) levels in
CPCs were cultured for 48 h, treated with EGF (EGF+) or without (EGF−) EGF and kinase inhib
by immunoblotting (C). (D, E) Effects of kinase inhibitors on GFAP levels in necdin-null CPCs. CP
with EGF and kinase inhibitors as in B. Expression of GFAP, necdin, and γ-tubulin (γ-Tub) wa
normalized to γ-tubulin levels. Each value represents themean± SEM, n=4. P-valueswere ca
at P ≥0.05.expression levels of the GFAP protein in necdin-null CPCs treated with
CT-1, indicating that the GFAP protein level correlates well with the
extent of astrocyte differentiation.
We also examined neuronal differentiation of EGF-treated CPCs
by withdrawing both bFGF and EGF (Fig. 6D–F). EGF markedly re-
duced the population of βIII-tubulin+ neurons, suggesting that EGF
prevents neuronal differentiation of CPCs. However, there was no
signiﬁcant difference in the number of differentiated βIII-tubulin+
neurons between wild-type and necdin-null CPCs. These observa-
tions suggest that necdin speciﬁcally suppresses EGF-promoted as-
trocyte differentiation of CPCs.
To investigate whether necdin-null mice express high GFAP
levels in the cortex in vivo during the neonatal period, we analyzed
cortical GFAP levels at postnatal day 4 by immunoblotting. We
found no signiﬁcant difference in the GFAP level between wild-
type and necdin-null mice (Fig. S4A, B). Intriguingly, EGF mRNA
levels in necdin-null cortex in vivo were reduced by 54% at E18.5, a
late stage of cortical development when astrocyte differentiation
occurs (Fig. S4C). Expression of EGF mRNA in primary CPCs was
also reduced by 50% (Fig. S4D). These results suggest that necdin-
null CPCs express low levels of EGF mRNA to prevent astrocyte
hyperproliferation due to enhanced EGFR signaling via a negative
feedback regulation.s on EGFR signalingpathways. CPCswere incubated for 48 h and treatedwith EGF for 5min.
d PI3K inhibitor (PIKI, LY294002; 20 μM) were added to the medium 30 min before EGF
CPCs were analyzed by immunoblotting. (B, C) GFAP expression in CT-1-treated CPCs.
itors for 6 h, and incubated with CT-1 for 48 h (B). GFAP expression in CPCs was analyzed
Cs prepared fromwild-type (NdnWT) and necdin-null (Ndn KO) E14.5micewere treated
s analyzed by immunoblotting (D) and quantiﬁed by densitometry (E). GFAP levels were
lculated using one-way ANOVA followed by Tukey–Kramer post hoc test. NS, not signiﬁcant
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enhanced in necdin-null CPCs
To determine whether EGF-promoted astrocyte differentiation is
mediated by the EGFR signaling pathway in CPCs, we used the EGFR ty-
rosine kinase inhibitor (geﬁtinib), MEK1/2 inhibitor (U0126), and PI3K
inhibitor (LY294002). We ﬁrst examined the effects of these inhibitors
on EGF-induced phosphorylation levels of EGFR, ERK and Akt by immu-
noblot analysis (Fig. 7A). Autophosphorylation of EGFR was detected
5 min after EGF stimulation in CPCs treated with the MEK inhibitor
and the PI3K inhibitor but not in those treated with the EGFR tyrosine
kinase inhibitor. As expected, phosphorylation of ERKandAktwashard-
ly detected in EGF-stimulated CPCs treated with the inhibitors of MEK
and PI3K, respectively.
We then analyzed the effects of these kinase inhibitors on astrocyte
differentiation by immunoblot assay. CPCs were treated with EGF in the
presence or absence of these inhibitors for 6 h and then with CT-1 for
48 h (Fig. 7B). The GFAP levels in EGF-stimulated CPCs increased appre-
ciablywhen incubated in the absence of the inhibitors or in the presence
of the PI3K inhibitor (Fig. 7C). These observations indicate that EGF-
promoted astrocyte differentiation is mediated by the EGFR/ERK signal-
ing pathway in CPCs.
To test whether the EGFR/RAS/MEK/ERK pathway mediates EGF-
promoted enhancement of the GFAP levels in necdin-null CPCs, we
treated CPCs with EGF and these kinase inhibitors (Fig. 7D, E). The
EGF-dependent increase in the GFAP levels was signiﬁcantly enhanced
(1.54 times the wild-type control level) in necdin-null CPCs, and this
enhancementwas completely blocked byEGFR tyrosine kinase inhibitor
(geﬁtinib) or MEK1/2 inhibitor (U0126), but not by PI3K inhibitor
(LY294002). These results suggest that necdin suppresses astrocyte
differentiation through attenuation of the EGFR/RAS/MEK/ERK signal
transduction.3.8. Necdin antagonizes astrocyte differentiation promoted by transient
overexpression of EGFR in CPCs
Sustained activation of the EGFR/RAS/ERK pathway is involved in
astrocyte proliferation and pathogenesis of gliomas [33,34]. Thus, we
investigated whether astrocyte differentiation of primary CPCs is
promoted by overexpression of EGFR and an EGFR mutant (EGFRΔNT)
lacking the N-terminal ligand-binding domain (L1), which is equivalent
to human glioblastoma-associated EGFR variant III (EGFRvIII) (Fig. 8A).
CPCs were transiently transfected with cDNAs encoding wild-type
EGFR, kinase-dead K723R mutant, and EGFRΔNT by electroporation.
Autophosphorylation of wild-type EGFR and EGFRΔNT mutant, but
not that of the KR mutant, was detected 12 h after transfection by im-
munoblot analysis of phospho-EGFR (Fig. 8B).
We analyzed whether forced expression of EGFR and EGFR mutants
enhances astrocyte differentiation. Transiently transfected CPCs were
incubated for 24 h and then treated with CT-1 for 48 h (Fig. 8C). Immu-
nocytochemistry showed that overexpression of wild-type EGFR or
EGFRΔNT increased the GFAP immunoreactivity in transfected td-
Tomato+ CPCs (Fig. 8D). These cells exhibitedmorphological character-
istics of differentiated astrocytes such as extended processes and larger
cell bodies. Consistent with thesemorphological changes, GFAP expres-
sion levels increasedmarkedly in CPCs transfectedwith wild-type EGFR
or EGFRΔNT as analyzed by immunoblotting (Fig. 8E).
We then examined whether necdin prevents EGFR- or EGFRΔNT-
promoted astrocyte differentiation of CPCs (Fig. 8F, G). We found that
a necdin mutant lacking residues 144–184 located in the MAGE homol-
ogy domain (necdinΔEB) [26] failed to interact with EGFR (Fig. S5).
Thus,we used this EGFR binding-defectivemutant as a negative control.
Necdin strongly decreased the GFAP level to near basal level of td-
Tomato+ control in EGFR-overexpressing CPCs. Similarly, necdin re-
duced the GFAP level in EGFRΔNT-overexpressing CPCs. In contrast,necdinΔEB had no antagonizing effects. In this analysis, neither necdin
nor necdinΔEB affected the basal GFAP level in transfected CPCs.
We analyzed whether human MAGEA1, a MAGE family member
expressed in many cancers, affects EGFR-mediated astrocyte differenti-
ation induced by EGFR overexpression. MAGEA1 bound to both EGFR
and kinase-dead mutant (Fig. S6A). In contrast to necdin, MAGEA1 en-
hanced EGFR-induced GFAP expression, and coexpression of necdin
strongly antagonized the effect of MAGEA1 (Fig. S6B, C). These results
suggest that necdin and MAGEA1 exert opposite effects on the EGFR
signaling.
We also examined the GFAP expression levels in wild-type and
necdin-null CPCs overexpressing EGFR (Fig. 8H, I). The GFAP levels in-
creased by 57% in necdin-null CPCs overexpressing EGFR. The increase
in the GFAP level was completely suppressed by coexpression of necdin,
but not of necdinΔEB. These results suggest that endogenous necdin in
CPCs acts as an intrinsic suppressor of astrocyte differentiation induced
by EGFR overexpression,
4. Discussion
EGFR signaling in CPCs plays an important role in astrocyte differen-
tiation during the late embryonic period when the transition from
neurogenesis to gliogenesis occurs in developing cortex [9]. Further-
more, the RAS/ERK signaling pathway is involved in astrocyte differen-
tiation during brain development [35–38]. These ﬁndings indicate that
the RAS/MEK/ERK signaling pathway is involved in the control of astro-
cyte differentiation during cortical development. Necdin suppresses the
EGFR/ERK signaling pathway by interacting with autophosphorylated
EGFR in EGF-responsive CPCs. Thus, we propose that necdin is an intrin-
sic suppressor of the EGF/EGFR signaling in CPCs to restrict astrocyte
differentiation during the late period of cortical development.
Stimulation of EGFR by EGF induces autophosphorylation of the C-
tail followed by activation of downstream signaling pathways including
the RAS/MEK/ERK and PI3K/Akt cascades [39]. Necdin suppresses the
EGFR/ERK signal transduction by interactingwith the C-terminal region
of the TKD. Necdin interacts with the TKD of EGFR only in its activated
state, and the interaction is enhanced in the absence of the C-tail. This
suggests that the unphosphorylated C-tail interferes with the interac-
tion betweennecdin and the TKD. This idea is supported by the previous
observations on the conformational changes of the C-tail and TKD in in-
active and active states of EGFR [40]. We speculate that necdin binds to
the TKD when autophosphorylation of the C-tail uncovers the necdin-
binding site on the TKD. Thus, the C-tailmay serve as amolecular switch
to control the interaction between necdin and the TKD in CPCs (Fig. 9).
The TKD of EGFR consists of N-terminal (N-lobe) and C-terminal (C-
lobe) regions, and the N-lobe contains the speciﬁc sites for the tyrosine
kinase activity such as ATP-binding site, C-helix, and phosphate-binding
loop (P-loop) [41,42]. Necdin binds to the C-terminal end of the C-lobe,
and this location may be critical for the reduced interaction between
autophosphorylated C-tail and Grb2 without affecting the tyrosine ki-
nase activity. Intriguingly, the EGFR feedback inhibitor MIG6 (also
known as RALT or ERRFI1), like necdin, binds to the TKD when EGFR is
activated [43]. However, MIG6, unlike necdin, inhibits the tyrosine ki-
nase activity of EGFR to suppress both RAS/ERK and PI3K/Akt pathways
[44]. This may be attributable to the structural characteristics of MIG6
associated with the allosteric control of the EGFR kinase activity [43,
45]. The differences between necdin and MIG6 imply that necdin is a
unique inhibitor of the EGFR/RAS/ERK signaling pathway linked to
cellular proliferation but not of the PI3K/Akt signaling pathway linked
to cell survival. These ﬁndings are consistent with the notion that
necdin suppresses cell proliferation and maintains cell survival.
Neural precursor cells in the embryonic forebrain of necdin-null
mice are highly proliferative in vivo during the early period of develop-
mentwhen neurogenesis occurs actively [16,17]. Necdin suppresses the
proliferation of CPCs by increasing p16 expression through interaction
with the p16 transcriptional repressor Bmi1 and by reducing Cdk1
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E2F1 [17], suggesting that necdin prevents hyperproliferation of early
CPCs, which are competent to differentiate into neurons, bymodulating
the activities of these cell cycle regulatory proteins. The present study
provides evidence that necdin suppresses astrocyte generation from
EGF-responsive CPCs through attenuation of the EGFR/ERK pathway.Thus, necdin may control the EGFR/ERK signaling pathway in late
CPCs, which are competent to differentiate into astrocytes. We propose
that necdin ﬁne-tunes the regulatory systems involved in neurogenesis
and gliogenesis at different stages of normal cortical development.
Numerous studies have indicated that EGFR signaling is central to
the pathogenesis of many cancers in which genetic alterations of EGFR
Fig. 9.A schematicmodel for suppression of EGFR signaling by necdin. Necdin binds to EGF-activated EGFR via the TKDC-lobe andblocks the interaction between EGFR andGrb2, resulting
in the suppression of the RAS/ERK signaling pathway. For details, see Discussion. ICD, intracellular domain; TKD, tyrosine kinase domain; P, phospho-tyrosine; Ndn+, wild-type necdin;
Ndn−, necdin deﬁciency.
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more, the importance of EGFR signaling in cancer progression is
supported by the fact that several anticancer drugs such as geﬁtinib
and erlotinib target the EGFR TKD [47]. The present study has clariﬁed
that necdin acts as an endogenous suppressor of EGFR signaling.
Furthermore, necdin is not expressed in many cancer cells, where the
necdin gene is hypermethylated [48]. Theseﬁndings raise thepossibility
that necdin potentially suppresses malignant transformation induced
by enhanced EGFR signaling in various types of cancers. As shown in
this study, necdin suppresses EGFR overexpression-induced astrocyte
differentiation, whereas MAGEA1, another MAGE family member
expressed in many kinds of malignant tumors [49], promotes it, sug-
gesting that necdin and MAGEA1 exert opposite effects on EGFR-
mediated signaling events. Thus, it is tempting to speculate that these
different types ofMAGE familymembers antagonistically controlmalig-
nant transformation induced by EGFR or its mutants.
Dysregulation of EGFR signal transduction has been suggested to
contribute to the etiology of brain tumors including gliomas [33]. Aber-
rant activation of the RAS/MEK/ERK pathway is also involved in the
pathogenesis of astrocytoma or glioma [34,38]. On the other hand,
necdin is not expressed in many cell lines derived from neural cell-
derived tumors such as glioma, neuroblastoma, pheochromocytoma,
and ependymoma [25,50,51]. A network modeling study of DNA copyFig. 8. Necdin antagonizes astrocyte differentiation induced by EGFR overexpression in CPCs. (A
EGFRN-terminal (residues 6–273) deletionmutant; L1/2, ligand-binding domain 1/2 (Ligand B
domain; CT, C-terminal domain. (B) Autophosphorylation of EGFR and ΔNT mutant. CPCs were
tion, and expression of phospho-EGFR (pEGFR) and EGFR in transfected CPCswas analyzed 12 h
sion in EGFR-overexpressing CPCs. CPCswere transiently transfectedwith cDNAs forwild-type E
in transfected CPCs was analyzed by triple staining of GFAP (green), td-Tomato (red), and nuc
expression in td-Tomato+ cells (yellow in D). Arrowheads point to td-Tomato+ CPCs. Scale ba
transfected with combinations of cDNAs for wild-type EGFR, EGFRΔNT, FLAG-necdin (Ndn) an
was analyzed immunoblotting (F). Necdin-immunoreactive bands at 46, 42, 34 kDa are of FLAG-
by densitometry (G). The broken line indicates the basal GFAP expression in CPCs expressing t
EGFR overexpression. CPCs prepared fromwild-type (NdnWT) and necdin-null (Ndn KO) mice
sion levelswere analyzed. Each value represents themean±SEM, n=4(G, I). P-valueswere ca
at P ≥0.05.number aberrations implicates necdin in suppressing cell growth of
glioblastomas [52]. Furthermore, reduced NDN expression in low
grade gliomas strongly correlates with reduced overall survival of
patients with gliomas [53]. The gene overexpression experiments
demonstrated that necdin strongly prevents astrocyte differentiation
induced by overexpression of wild-type EGFR or its mutant equivalent
to human EGFR variant III (EGFRvIII) in CPCs. Overexpression of EGFR
and its deletion mutants such as EGFRvIII is commonly found in
glioblastomas [33]. Gliomas are proposed to arise from neural stem
cells that are generated from glial progenitor cells or astrocytes via
reprogrammed processes [34,54]. Thus, we infer that necdin serves as
a tumor suppressor that controls the EGFR/ERK pathway in astrocyte
progenitors to prevent their malignant transformation.
The human necdin gene (NDN) is located in chromosome 15q11.2-
q12 [55], a region deleted in Prader–Willi syndrome (PWS), a typical ge-
nomic imprinting-associated neurodevelopmental disorder.NDN is ma-
ternally imprinted, expressed only from the paternal allele, and not
expressed in individuals with PWS [56,57]. Although patients with
PWS exhibit symptoms due to hypothalamic abnormalities such as hy-
perphagia and hypogonadism, there is limited information on neuro-
pathological lesions in PWS. In contrast, the mouse necdin gene (Ndn)
located in chromosome 7C is also imprinted, and paternal Ndn-mutant
mice display failure-to-thrive and early neonatal lethality [58,59].) Diagrams of EGFR and its mutants. WT, wild-type EGFR; KR, EGFR K723R mutant; ΔNT,
D); TM, transmembrane domain; Necdin BD, necdin-binding domain; TKD, tyrosine kinase
transiently transfected with wild-type EGFR, KR mutant and ΔNTmutant by electropora-
after transfection by immunoblotting. Tmt, td-Tomato vector control. (C–E) GFAP expres-
GFR and itsmutants, cultured for 24 h, and treatedwith CT-1 for 48 h (C). GFAP expression
lear DNA (blue) (D) and immunoblotting (E). Triple-stained images are merged for GFAP
r, 20 μm. (F, G) Effect of necdin on EGFR-induced GFAP expression. CPCs were transiently
d NdnΔEB (EGFR binding-defective necdin mutant). GFAP expression in transfected CPCs
necdin, endogenous necdin, and necdinΔEB, respectively. GFAP expressionwas quantiﬁed
d-Tomato alone (=1). (H, I) Effect of endogenous necdin on GFAP expression induced by
at E14.5 were transfected with EGFR, FLAG-necdin (Ndn) and NdnΔEB, and GFAP expres-
lculated using one-wayANOVA followedby Tukey–Kramer post hoc test. NS, not signiﬁcant
106 I. Fujimoto et al. / Cellular Signalling 28 (2016) 94–107Moreover, PWS model mice created by transgene insertion or PWS
imprinting-center mutation fail to express necdin and display early
postnatal lethality [60,61]. The Ndn-mutant mice, mostly examined at
their embryonic and neonatal stages, exhibit various morphological
and functional abnormalities, in which several are reminiscent of PWS
[22,59,62–72]. Thus, primary cells such as CPCs prepared from necdin-
null mice are indispensable for dissecting molecular mechanisms
underlying these abnormalities. We assume that other stem/progenitor
cells expressing both necdin and EGFR also exhibit enhanced EGFR
signaling in the absence of endogenous necdin. The present ﬁndings
warrant close examination of the pathologies associated with dysregu-
lation of EGFR signaling in PWS.
5. Conclusions
EGFR and necdin are coexpressed in primary CPCs. Necdin binds to
autophosphorylated EGFR via its tyrosine kinase domain. In necdin-
null CPCs, the EGFR/ERK pathway is activated through increased inter-
action between EGFR and Grb2. Furthermore, EGF-promoted astrocyte
differentiation is accelerated via the EGFR/ERK pathway in necdin-null
CPCs. Necdin restrains astrocyte differentiation induced by overexpres-
sion of EGFR or its EGF binding-defective mutant in CPCs. These results
suggest that necdin is an intrinsic suppressor of EGFR/ERK signaling in
CPCs under physiological and pathological conditions.
Funding
Thisworkwas supported by aGrant-in-Aid for Scientiﬁc ResearchB2
(24300134; to K.Y.) from the Japan Society for the Promotion of Science.
Author contributions
I.F., K.H., K.F., M.Y., and K.Y. conceived and designed the research. I.F.
performed the experiments. I.F., K.H. and K.F. analyzed the data. I.F. and
K.Y. wrote the manuscript.
Conﬂict of interest
The authors declare no competing ﬁnancial interests.
Acknowledgments
Weare grateful to all the past and presentmembers of the K.Y. group
for discussions, research information and experimental materials.
Appendix A. Supplementarydata
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2015.11.016.
References
[1] B.A. Reynolds,W. Tetzlaff, S.Weiss, Amultipotent EGF-responsive striatal embryonic
progenitor cell produces neurons and astrocytes, J. Neurosci. 12 (1992) 4565–4574.
[2] V. Tropepe, M. Sibilia, B.G. Ciruna, J. Rossant, E.F. Wagner, D. van der Kooy, Distinct
neural stem cells proliferate in response to EGF and FGF in the developing mouse
telencephalon, Dev. Biol. 208 (1999) 166–188.
[3] D. Maric, I. Maric, Y.H. Chang, J.L. Barker, Prospective cell sorting of embryonic rat
neural stem cells and neuronal and glial progenitors reveals selective effects of
basic ﬁbroblast growth factor and epidermal growth factor on self-renewal and dif-
ferentiation, J. Neurosci. 23 (2003) 240–251.
[4] T.J. Kilpatrick, P.F. Bartlett, Cloned multipotential precursors from the mouse cere-
brum require FGF-2, whereas glial restricted precursors are stimulated with either
FGF-2 or EGF, J. Neurosci. 15 (1995) 3653–3661.
[5] R.C. Burrows, D. Wancio, P. Levitt, L. Lillien, Response diversity and the timing of
progenitor cell maturation are regulated by developmental changes in EGFR expres-
sion in the cortex, Neuron 19 (1997) 251–267.
[6] X. Qian, Q. Shen, S.K. Goderie, W. He, A. Capela, A.A. Davis, S. Temple, Timing of CNS
cell generation: a programmed sequence of neuron and glial cell production from
isolated murine cortical stem cells, Neuron 28 (2000) 69–80.[7] L. Lillien, H. Raphael, BMP and FGF regulate the development of EGF-responsive
neural progenitor cells, Development 127 (2000) 4993–5005.
[8] Y. Sun, S.K. Goderie, S. Temple, Asymmetric distribution of EGFR receptor duringmi-
tosis generates diverse CNS progenitor cells, Neuron 45 (2005) 873–886.
[9] S. Temple, The development of neural stem cells, Nature 414 (2001) 112–117.
[10] H.I. Kornblum, R.J. Hussain, J.M. Bronstein, C.M. Gall, D.C. Lee, K.B. Seroogy, Prenatal
ontogeny of the epidermal growth factor receptor and its ligand, transforming
growth factor alpha, in the rat brain, J. Comp. Neurol. 380 (1997) 243–261.
[11] D.W. Threadgill, A.A. Dlugosz, L.A. Hansen, T. Tennenbaum, U. Lichti, D. Yee, C.
LaMantia, T. Mourton, K. Herrup, R.C. Harris, et al., Targeted disruption of mouse
EGF receptor: effect of genetic background on mutant phenotype, Science 269
(1995) 230–234.
[12] M. Sibilia, J.P. Steinbach, L. Stingl, A. Aguzzi, E.F.Wagner, A strain-independent postna-
tal neurodegeneration inmice lacking the EGF receptor, EMBO J. 17 (1998) 719–731.
[13] J. Viti, A. Feathers, J. Phillips, L. Lillien, Epidermal growth factor receptors control
competence to interpret leukemia inhibitory factor as an astrocyte inducer in devel-
oping cortex, J. Neurosci. 23 (2003) 3385–3393.
[14] K. Maruyama, M. Usami, T. Aizawa, K. Yoshikawa, A novel brain-speciﬁc mRNA
encoding nuclear protein (necdin) expressed in neurally differentiated embryonal
carcinoma cells, Biochem. Biophys. Res. Commun. 178 (1991) 291–296.
[15] T. Uetsuki, K. Takagi, H. Sugiura, K. Yoshikawa, Structure and expression of
the mouse necdin gene. Identiﬁcation of a postmitotic neuron-restrictive core pro-
moter, J. Biol. Chem. 271 (1996) 918–924.
[16] Z. Huang, K. Fujiwara, R. Minamide, K. Hasegawa, K. Yoshikawa, Necdin controls
proliferation and apoptosis of embryonic neural stem cells in an oxygen tension-
dependent manner, J. Neurosci. 33 (2013) 10362–10373.
[17] R. Minamide, K. Fujiwara, K. Hasegawa, K. Yoshikawa, Antagonistic interplay be-
tween necdin and Bmi1 controls proliferation of neural precursor cells in the em-
bryonic mouse neocortex, PLoS One 9 (2014) e84460.
[18] H. Taniura, N. Taniguchi, M. Hara, K. Yoshikawa, Necdin, a postmitotic neuron-
speciﬁc growth suppressor, interacts with viral transforming proteins and cellular
transcription factor E2F1, J. Biol. Chem. 273 (1998) 720–728.
[19] H. Taniura, K. Matsumoto, K. Yoshikawa, Physical and functional interactions of neu-
ronal growth suppressor necdin with p53, J. Biol. Chem. 274 (1999) 16242–16248.
[20] M. Kurita, T. Kuwajima, I. Nishimura, K. Yoshikawa, Necdin downregulates cdc2 ex-
pression to attenuate neuronal apoptosis, J. Neurosci. 26 (2006) 12003–12013.
[21] K. Hasegawa, K. Yoshikawa, Necdin regulates p53 acetylation via Sirtuin1 to modu-
late DNA damage response in cortical neurons, J. Neurosci. 28 (2008) 8772–8784.
[22] K. Kuwako, A. Hosokawa, I. Nishimura, T. Uetsuki, M. Yamada, S. Nada, M. Okada, K.
Yoshikawa, Disruption of the paternal necdin gene diminishes TrkA signaling for
sensory neuron survival, J. Neurosci. 25 (2005) 7090–7099.
[23] Y.L. Deribe, P. Wild, A. Chandrashaker, J. Curak, M.H. Schmidt, Y. Kalaidzidis, N.
Milutinovic, I. Kratchmarova, L. Buerkle, M.J. Fetchko, P. Schmidt, S. Kittanakom,
K.R. Brown, I. Jurisica, B. Blagoev, M. Zerial, I. Stagljar, I. Dikic, Regulation of epider-
mal growth factor receptor trafﬁcking by lysine deacetylase HDAC6, Sci. Signal. 2
(2009) ra84.
[24] M. Niinobe, K. Koyama, K. Yoshikawa, Cellular and subcellular localization of necdin
in fetal and adult mouse brain, Dev. Neurosci. 22 (2000) 310–319.
[25] T. Aizawa, K. Hasegawa, T. Ohkumo, S. Haga, K. Ikeda, K. Yoshikawa, Neural stem
cell-like gene expression in a mouse ependymoma cell line transformed by
human BK polyomavirus, Cancer Sci. 102 (2011) 122–129.
[26] H. Taniura, M. Kobayashi, K. Yoshikawa, Functional domains of necdin for protein–
protein interaction, nuclear matrix targeting, and cell growth suppression, J. Cell.
Biochem. 94 (2005) 804–815.
[27] I. Gur, K. Fujiwara, K. Hasegawa, K. Yoshikawa, Necdin promotes ubiquitin-
dependent degradation of PIAS1 SUMO E3 ligase, PLoS One 9 (2014) e99503.
[28] K.K. Johe, T.G. Hazel, T. Muller, M.M. Dugich-Djordjevic, R.D. McKay, Single factors
direct the differentiation of stem cells from the fetal and adult central nervous sys-
tem, Genes Dev. 10 (1996) 3129–3140.
[29] A. Bonni, Y. Sun, M. Nadal-Vicens, A. Bhatt, D.A. Frank, I. Rozovsky, N. Stahl, G.D.
Yancopoulos, M.E. Greenberg, Regulation of gliogenesis in the central nervous sys-
tem by the JAK-STAT signaling pathway, Science 278 (1997) 477–483.
[30] K. Nakashima, S. Wiese, M. Yanagisawa, H. Arakawa, N. Kimura, T. Hisatsune, K.
Yoshida, T. Kishimoto, M. Sendtner, T. Taga, Developmental requirement of gp130
signaling in neuronal survival and astrocyte differentiation, J. Neurosci. 19 (1999)
5429–5434.
[31] W. Ochiai, M. Yanagisawa, T. Takizawa, K. Nakashima, T. Taga, Astrocyte differentia-
tion of fetal neuroepithelial cells involving cardiotrophin-1-induced activation of
STAT3, Cytokine 14 (2001) 264–271.
[32] F. Barnabe-Heider, J.A. Wasylnka, K.J. Fernandes, C. Porsche, M. Sendtner, D.R.
Kaplan, F.D. Miller, Evidence that embryonic neurons regulate the onset of cortical
gliogenesis via cardiotrophin-1, Neuron 48 (2005) 253–265.
[33] M.K. Nicholas, R.V. Lukas, N.F. Jafri, L. Faoro, R. Salgia, Epidermal growth factor recep-
tor-mediated signal transduction in the development and therapy of gliomas, Clin.
Cancer Res. 12 (2006) 7261–7270.
[34] Y. Zhu, L.F. Parada, The molecular and genetic basis of neurological tumours, Nat.
Rev. Cancer 2 (2002) 616–626.
[35] B. Dasgupta, D.H. Gutmann, Neuroﬁbromin regulates neural stem cell proliferation,
survival, and astroglial differentiation in vitro and in vivo, J. Neurosci. 25 (2005)
5584–5594.
[36] X. Li, J.M. Newbern, Y. Wu, M. Morgan-Smith, J. Zhong, J. Charron, W.D. Snider, MEK
is a key regulator of gliogenesis in the developing brain, Neuron 75 (2012)
1035–1050.
[37] Y. Wang, E. Kim, X. Wang, B.G. Novitch, K. Yoshikawa, L.S. Chang, Y. Zhu, ERK inhi-
bition rescues defects in fate speciﬁcation of Nf1-deﬁcient neural progenitors and
brain abnormalities, Cell 150 (2012) 816–830.
107I. Fujimoto et al. / Cellular Signalling 28 (2016) 94–107[38] S. Li, P. Mattar, R. Dixit, S.O. Lawn, G.Wilkinson, C. Kinch, D. Eisenstat, D.M. Kurrasch,
J.A. Chan, C. Schuurmans, RAS/ERK signaling controls proneural genetic programs in
cortical development and gliomagenesis, J. Neurosci. 34 (2014) 2169–2190.
[39] R.N. Jorissen, F. Walker, N. Pouliot, T.P. Garrett, C.W. Ward, A.W. Burgess, Epidermal
growth factor receptor: mechanisms of activation and signalling, Exp. Cell Res. 284
(2003) 31–53.
[40] N. Jura, N.F. Endres, K. Engel, S. Deindl, R. Das, M.H. Lamers, D.E. Wemmer, X. Zhang,
J. Kuriyan, Mechanism for activation of the EGF receptor catalytic domain by the
juxtamembrane segment, Cell 137 (2009) 1293–1307.
[41] X. Zhang, J. Gureasko, K. Shen, P.A. Cole, J. Kuriyan, An allosteric mechanism for ac-
tivation of the kinase domain of epidermal growth factor receptor, Cell 125 (2006)
1137–1149.
[42] M.A. Lemmon, J. Schlessinger, K.M. Ferguson, The EGFR family: not so prototypical
receptor tyrosine kinases, Cold Spring Harb. Perspect. Biol. 6 (2014) a020768.
[43] X. Zhang, K.A. Pickin, R. Bose, N. Jura, P.A. Cole, J. Kuriyan, Inhibition of the EGF re-
ceptor by binding of MIG6 to an activating kinase domain interface, Nature 450
(2007) 741–744.
[44] O. Segatto, S. Anastasi, S. Alema, Regulation of epidermal growth factor receptor sig-
nalling by inducible feedback inhibitors, J. Cell Sci. 124 (2011) 1785–1793.
[45] S. Anastasi, M.F. Baietti, Y. Frosi, S. Alema, O. Segatto, The evolutionarily conserved
EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity,
Oncogene 26 (2007) 7833–7846.
[46] N. Normanno, A. De Luca, C. Bianco, L. Strizzi, M. Mancino, M.R. Maiello, A.
Carotenuto, G. De Feo, F. Caponigro, D.S. Salomon, Epidermal growth factor receptor
(EGFR) signaling in cancer, Gene 366 (2006) 2–16.
[47] R.S. Herbst, M. Fukuoka, J. Baselga, Geﬁtinib—a novel targeted approach to treating
cancer, Nat. Rev. Cancer 4 (2004) 956–965.
[48] L.E. De Faveri, C.D. Hurst, F.M. Platt, C.F. Taylor, J.A. Roulson,M. Sanchez-Carbayo,M.A.
Knowles, E.J. Chapman, Putative tumour suppressor gene necdin is hypermethylated
and mutated in human cancer, Br. J. Cancer 108 (2013) 1368–1377.
[49] P. Chomez, O. De Backer, M. Bertrand, E. De Plaen, T. Boon, S. Lucas, An overview of
the MAGE gene family with the identiﬁcation of all human members of the family,
Cancer Res. 61 (2001) 5544–5551.
[50] T. Aizawa, K. Maruyama, H. Kondo, K. Yoshikawa, Expression of necdin, an embryo-
nal carcinoma-derived nuclear protein, in developing mouse brain, Brain Res. Dev.
Brain Res. 68 (1992) 265–274.
[51] M. Kobayashi, H. Taniura, K. Yoshikawa, Ectopic expression of necdin induces differ-
entiation of mouse neuroblastoma cells, J. Biol. Chem. 277 (2002) 42128–42135.
[52] R. Jornsten, T. Abenius, T. Kling, L. Schmidt, E. Johansson, T.E. Nordling, B.
Nordlander, C. Sander, P. Gennemark, K. Funa, B. Nilsson, L. Lindahl, S. Nelander,
Network modeling of the transcriptional effects of copy number aberrations in glio-
blastoma, Mol. Syst. Biol. 7 (2011) 486.
[53] X. Li, S.C. Hughes, R. Wevrick, Evaluation of melanoma antigen (MAGE) gene ex-
pression in human cancers using The Cancer Genome Atlas, Cancer Genet. 208
(2015) 25–34.
[54] N. Sanai, A. Alvarez-Buylla, M.S. Berger, Neural stem cells and the origin of gliomas,
N. Engl. J. Med. 353 (2005) 811–822.
[55] Y. Nakada, H. Taniura, T. Uetsuki, J. Inazawa, K. Yoshikawa, The human chromosomal
gene for necdin, a neuronal growth suppressor, in the Prader–Willi syndrome dele-
tion region, Gene 213 (1998) 65–72.[56] P. Jay, C. Rougeulle, A. Massacrier, A. Moncla, M.G. Mattei, P. Malzac, N. Roeckel, S.
Taviaux, J.L. Lefranc, P. Cau, P. Berta, M. Lalande, F. Muscatelli, The human necdin
gene, NDN, is maternally imprinted and located in the Prader–Willi syndrome chro-
mosomal region, Nat. Genet. 17 (1997) 357–361.
[57] H.R. MacDonald, R. Wevrick, The necdin gene is deleted in Prader–Willi syndrome
and is imprinted in human and mouse, Hum. Mol. Genet. 6 (1997) 1873–1878.
[58] M. Gerard, L. Hernandez, R. Wevrick, C.L. Stewart, Disruption of the mouse necdin
gene results in early post-natal lethality, Nat. Genet. 23 (1999) 199–202.
[59] F. Muscatelli, D.N. Abrous, A. Massacrier, I. Boccaccio, M. Le Moal, P. Cau, H. Cremer,
Disruption of the mouse necdin gene results in hypothalamic and behavioral alter-
ations reminiscent of the human Prader–Willi syndrome, Hum.Mol. Genet. 9 (2000)
3101–3110.
[60] T. Yang, T.E. Adamson, J.L. Resnick, S. Leff, R. Wevrick, U. Francke, N.A. Jenkins, N.G.
Copeland, C.I. Brannan, A mouse model for Prader–Willi syndrome imprinting-
centre mutations, Nat. Genet. 19 (1998) 25–31.
[61] J.M. Gabriel, M. Merchant, T. Ohta, Y. Ji, R.G. Caldwell, M.J. Ramsey, J.D. Tucker, R.
Longnecker, R.D. Nicholls, A transgene insertion creating a heritable chromosome
deletion mouse model of Prader–Willi and Angelman syndromes, Proc. Natl. Acad.
Sci. U. S. A. 96 (1999) 9258–9263.
[62] J. Ren, S. Lee, S. Pagliardini, M. Gerard, C.L. Stewart, J.J. Greer, R. Wevrick, Absence of
Ndn, encoding the Prader–Willi syndrome-deleted gene necdin, results in congeni-
tal deﬁciency of central respiratory drive in neonatal mice, J. Neurosci. 23 (2003)
1569–1573.
[63] T. Kuwajima, I. Nishimura, K. Yoshikawa, Necdin promotes GABAergic neuron differ-
entiation in cooperation with Dlx homeodomain proteins, J. Neurosci. 26 (2006)
5383–5392.
[64] T. Kuwajima, K. Hasegawa, K. Yoshikawa, Necdin promotes tangential migration of
neocortical interneurons from basal forebrain, J. Neurosci. 30 (2010) 3709–3714.
[65] S. Zanella, F. Watrin, S. Mebarek, F. Marly, M. Roussel, C. Gire, G. Diene, M. Tauber, F.
Muscatelli, G. Hilaire, Necdin plays a role in the serotonergic modulation of the
mouse respiratory network: implication for Prader–Willi syndrome, J. Neurosci. 28
(2008) 1745–1755.
[66] A.A. Tennese, C.B. Gee, R.Wevrick, Loss of the Prader–Willi syndrome protein necdin
causes defective migration, axonal outgrowth, and survival of embryonic sympa-
thetic neurons, Dev. Dyn. 237 (2008) 1935–1943.
[67] N.L. Miller, R.Wevrick, P.L. Mellon, Necdin, a Prader–Willi syndrome candidate gene,
regulates gonadotropin-releasing hormone neurons during development, Hum.
Mol. Genet. 18 (2009) 248–260.
[68] J.R. Bush, R. Wevrick, Loss of necdin impairs myosin activation and delays cell polar-
ization, Genesis 48 (2010) 540–553.
[69] J. Aebischer, R. Sturny, D. Andrieu, A. Rieusset, F. Schaller, S. Geib, C. Raoul, F.
Muscatelli, Necdin protects embryonic motoneurons from programmed cell death,
PLoS One 6 (2011) e23764.
[70] K. Fujiwara, K. Hasegawa, T. Ohkumo, H. Miyoshi, Y.H. Tseng, K. Yoshikawa, Necdin
controls proliferation of white adipocyte progenitor cells, PLoS One 7 (2012) e30948.
[71] J.R. Bush, R. Wevrick, Loss of the Prader–Willi obesity syndrome protein necdin pro-
motes adipogenesis, Gene 497 (2012) 45–51.
[72] K. Hasegawa, T. Kawahara, K. Fujiwara, M. Shimpuku, T. Sasaki, T. Kitamura, K.
Yoshikawa, Necdin controls FoxO1 acetylation in hypothalamic arcuate neurons to
modulate the thyroid axis, J. Neurosci. 32 (2012) 5562–5572.
